99114-72-4

Usage

Uses

Used in Pharmaceutical Industry:
AKOS BC-1112 is used as an anti-inflammatory agent for its ability to inhibit the enzyme LTA4H, thereby reducing the formation of leukotrienes and alleviating inflammation.
Used in Oncology:
AKOS BC-1112 is used as an anticancer drug candidate due to its demonstrated inhibitory effects on the growth of various cancer cell lines, making it a promising option for cancer treatment development.
Used in Pulmonary Disease Treatment:
AKOS BC-1112 is used as a potential treatment for inflammatory lung diseases, such as chronic obstructive pulmonary disease, as it has shown the capability to reduce the production of pro-inflammatory cytokines and chemokines in relevant disease models.

InChI:InChI=1/C8H18N2O/c1-9-3-2-4-10-5-7-11-8-6-10/h9H,2-8H2,1H3

Upstream product

• 123-00-2 4-(3-Aminopropyl)morpholine 
• 124-38-9 carbon dioxide 
• 79-22-1 methyl chloroformate 
• 7357-67-7 4-(3-chloropropyl)morpholine 
• 74-89-5 methylamine 

Relevant academic research and scientific papers

Compounds and methods for inhibiting phosphate transport

Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Selective N-methylation of aliphatic amines with CO2 and hydrosilanes using nickel-phosphine catalysts

A method using CO2 and PhSiH3 for the methylation of primary and secondary aliphatic amines catalyzed by Ni (0) complexes was developed, selectively producing the monomethylated products in moderate to good yields. For that purpose, two catalysts were used: [(dippe)Ni(μ-H)]2 and the commercially available Ni(COD)2/dcype, both of which were rather efficient in this process. With a slight experimental modification, the reaction allowed the production of monomethylated ureas in good yields by using low amounts of PhSiH3. On the basis of the experimental results, we propose a possible reaction mechanism for the formation of the new C-N bond.

METHOD OF PREPARING POLY(ALKYLENE CARBONATE) VIA COPOLYMERIZATION OF CARBON DIOXIDE/EPOXIDE IN THE PRESENCE OF NOVEL COMPLEX

Provided is a method of preparing poly(alkylene carbonate) using a molecular weight regulator in a process of preparing a copolymer of carbon dioxide/epoxide using a novel complex synthesized from salen-type ligand including a quaternary ammonium salt as a catalyst. According to the present invention, even though the molecular weight regulator is used, an activity of the catalyst may be stably maintained, whereby the low molecular weight of poly(alkylene carbonate) having a desirable level may be effectively provided. In addition, it is expected that since the novel complex as the catalyst of the present invention has a simple structure as compared to the existing copolymerization catalyst, due to the economical preparation cost thereof, the novel complex may be effectively applied to a large-scale commercial process.

PYRIMIDINE DERIVATIVES

The invention concerns pyrimidine derivatives of Formula (I) wherein m is 0-3 and each Ris a group such as hydroxy, halogeno, trifluoromethyl and cyano; Ris hydrogen, halogeno or (1-6C)alkyl; n is 0-2 and each Ris a group such as hydroxy, halogeno, trifluoromethyl and cyano; p is 0-4; and Qis aryl or heteroaryl; or pharmaceutically acceptable salts or in vivo cleavable esters thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.